Setonix Technologies
Revolutionising spine and skull surgery with injectable, self-curing, patient-specific bioactive implants.
At a glance
-
Development stage
Prototype developed
-
Investment stage
Pre-Seed
-
UNSW affiliation
Spinout - staff led
-
Technology readiness level
TRL-4
OssioLink is a patented, injectable, self-curing bioactive implant for spinal and cranial repair.
Created by Setonix Technologies, it revolutionises bone regeneration and involves fewer complications. The technology has strong traction, including over AUD1 million in grant funding, AUD1.5 million in conditional private investment, and IP licensed from UNSW.
-
OssioLink uniquely combines self-curing and pre-moulding versatility to overcome limitations of current implant materials. Its bioactive fillers promote superior bone regeneration and antibacterial protection, while short fibres provide enhanced mechanical strength. Radiolucent, mouldable, and fully resorbable, OssioLink improves surgical outcomes and reduces complications. Revenue will be generated through direct hospital sales and original equipment manufacturer (OEM) licensing of surgical kits made under stringent regulatory quality systems.
-
- Current implants like PEEK and titanium don’t integrate with bone, cause imaging issues, or require complex fixation.
- Current implants often lead to repeat surgeries, increased hospital stays, and higher costs.
- Surgeons and hospitals urgently need mouldable, bioactive alternatives that reduce complications and promote natural healing, especially for irregular bone defects.
-
- Spinal and cranial surgeons at tertiary hospitals
- Also targeting orthopaedic implant development
- OEM partnerships will broaden distribution of metal-free, bone-integrative implants
-
- AUD1.5 million conditional investment (SoHi Ventures)
- Validated prototypes with ISO-standard mechanical testing
- Animal trials and biological preclinical studies underway
Discover more UNSW spinouts
Search our catalogue of active spinouts and tech for license.